Related Experiment Video
Updated: May 7, 2026
09:35
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Circulating CD36 is reduced in HNF1A-MODY carriers
Siobhan Bacon1, Ma P Kyithar, Jasmin Schmid
1Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.
Plos One
|September 27, 2013
Summary
Individuals with HNF1A-MODY diabetes have lower levels of the pro-atherogenic scavenger protein CD36 (sCD36). This finding may be linked to their favorable lipid profiles, suggesting a potentially reduced atherosclerosis risk compared to type 2 diabetes.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Disease Research
- Genetics of Diabetes
Background:
- Premature atherosclerosis is a major complication in type 2 diabetes mellitus.
- Maturity Onset Diabetes of the Young (MODY) constitutes ~2% of diabetes cases, with HNF1A mutations being the most common cause.
- Limited data exists on macrovascular disease prevalence in HNF1A-MODY, which typically lacks insulin resistance and dyslipidemia.
Purpose of the Study:
- To investigate soluble scavenger protein CD36 (sCD36) levels in HNF1A-MODY patients.
- To compare sCD36 levels with normoglycemic HNF1A-MODY negative family controls.
- To compare sCD36 levels with BMI-matched type 2 diabetes mellitus patients.
Main Methods:
- Recruited 37 participants with HNF1A-MODY diabetes.
- Compared sCD36 levels against normoglycemic HNF1A-MODY negative family controls.
- Compared sCD36 levels against BMI-matched type 2 diabetes mellitus patients.
Main Results:
- HNF1A-MODY participants were leaner with better lipid profiles (higher HDL, lower triglycerides) than controls and type 2 diabetes patients.
- Soluble CD36 (sCD36) levels were significantly lower in HNF1A-MODY participants compared to both control groups.
- Lower sCD36 was observed in HNF1A-MODY patients versus lean type 2 diabetes patients.
Conclusions:
- sCD36 is significantly lower in HNF1A-MODY diabetes patients compared to normoglycemic HNF1A-MODY negative controls and lean type 2 diabetes patients.
- The reduced sCD36 levels in HNF1A-MODY may be associated with their higher HDL cholesterol levels.
- This suggests a potentially lower pro-atherogenic risk profile in HNF1A-MODY diabetes.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...